Drug Profile
Research programme: antimalarial therapeutics - Medicines for Malaria Venture/Takeda/University of Melbourne
Alternative Names: ELQ-300Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Medicines for Malaria Venture; Takeda
- Developer Medicines for Malaria Venture; Takeda; University of Melbourne
- Class Ethers; Quinolones; Small molecules
- Mechanism of Action Electron transport complex III inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Malaria in Switzerland (PO)
- 28 Apr 2019 No recent reports of development identified for research development in Malaria in Japan (PO)
- 30 Mar 2017 Antimalarial therapeutics are still in research development stage for Malaria in Japan